Skip to content

Interest coverage at other companies

Vera Therapeutics logo
Vera TherapeuticsVERA
-50.7×+1,690×
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-9.3×+1.9×
LQD
Liquidia CorporationLQDA
-4.9×-1.6×
Arrowhead Research logo
Arrowhead ResearchARWR
-2.4×+0.9×
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
-55.3×-61.9×
ALN
Alnylam PharmaceuticalsALNY
3.4×+2.9×

Other financials

Income statement

See full
Revenue$77.7M+24.4%
Gross profit$71.2M+32.1%
Operating income$41.4M+89.6%
Net income$34.4M+47.2%
EPS (diluted)$0.25+56.3%

Balance sheet

See full
Cash & equivalents$41.0M-38.3%
Total debt$85.2M-7.9%
Total equity$567.6M+62.1%
Total assets$724.0M+43.4%

Cash flow

See full
Operating cash flow$32.6M+2,405%

Valuation

See full
Market cap$2.3B+78.5%
Enterprise value$2.34B+78.3%
P/E7.7×-24.6×
P/S7.7×+2.5×

Profitability

See full
Gross margin89.7%+1.5pp
Operating margin41.7%+29.4pp
Net margin100%+83.9pp

Returns & leverage

See full
Return on equity65%+53.8pp
Debt / equity0.2×-0.1×
Current ratio5.5×-0.4×

Where this comes from

Calculated from Aurinia Pharmaceuticals’s reported figures.

Based on trailing twelve months.

The official record: Aurinia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aurinia Pharmaceuticals's interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aurinia Pharmaceuticals's interest coverage?
Aurinia Pharmaceuticals (AUPH) reported interest coverage of 29.1× in Q1 2026.
How has Aurinia Pharmaceuticals's interest coverage changed year-over-year?
Aurinia Pharmaceuticals's interest coverage increased by 342.3% year-over-year, from 6.6× to 29.1×.
What is the long-term trend for Aurinia Pharmaceuticals's interest coverage?
Over 3 years (2022 to 2025), Aurinia Pharmaceuticals's interest coverage has grown at a -61.5% compound annual growth rate (CAGR), from -425.5× to 24.2×.
What does interest coverage mean?
Trailing-twelve-month operating income (EBIT) divided by interest expense. Measures how many times over the company can cover its interest payments from operating profit.